1Ogston K N,Miller I D,Payne S. A new histological grading system to assess response of breast cancr to primary chemotherapy:prognostic signficance and survival[J].Breast,2003,(05):320-327.doi:10.1016/S0960-9776(03)00106-1.
2Apple S K,Suthar F. How do we measure a residual tumor size in Histopathology (the gold standard) after neoadjuvant chemotherapy[J].Breast,2005,(03):370-376.
6Sperbre F,Weinstein Y,Sarid D. Peroperative clinical,mammographie and sonographic assessment of neoadjuvant chemotherapy response in breast cancer[J].Israel Medical Association Journal,2006,(05):342-346.
8Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst, 2000,92:205-216.
9Sakamoto G, Inaji H, Akiyama F, et al. General rules for clinical and pathological recording of breast cancer 2005. Breast Cancer, 2005,12 Suppl : 1-27.
10Wendy D, Constance L, Savannah P. Breast MRI for cancer detection and characterization:a review of evidence-based clinical applications. Acad Radiol, 2008, 15:408-416.
1Pearson G, Robinson F, Beers Gibson T, et al. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions[J]. Endocr Rev, 2001,22(2) :153-183.
2Liu SV, Melstrom L, Yao R, et al. Neoadjuvant Therapy forBreast Cancer[ J]. J Surg Oncol, 2010,101 (4) :283-291.
3Samuels Y, Diaz LA Jr, Schmidt-Kittler O, et al. Mutant PIK3CApromotes cell growth and invasion of human cancer cells [ J ]. Cancer Cell, 2005,7(6) :561-573.
4Forouzanfar M H,Foreman K J,Delossantos A M,et al. Breast and cervical cancer in 187 countries between 1980 and 2010:a systematic analysis[J]. Lancet, 2011,378( 9801 ) : 1461-1484.
5Hylton N M, Blume J D, Bernreuter W K, et al. Locally ad- vanced breast cancer:MR imaging for prediction of response to neoadjuvant chemotherapy--results from ACRIN 6657/I-SPY TRIAL[J]. Radiology,2012,263(3) :663-672.
6Heldahl M G, Bathen T F,Rydland J, et al. Prognostic value of pretreatment dynamic contrast-enhanced MR imaging in breast cancer patients receiving neoadjuvant chemotherapy: overall survival predicted from combined time course and volume anal ysis[J]. Acta Radiol,2010,51(6) :604-612.
7Hayashi Y, Takei H, Nozu S, et al. Analysis of complete re- sponse by MRI following neoadjuvant chemotherapy predicts pathological tumor responses differently for molecular sub types of breast cancer[J]. Oneol Lett, 2013,5 (1) : 83-89.
8Loo C E, Straver M E, Rodenhuis S, et al. Magnetic resonance imaging response monitoring of breast cancer during neoadju vant chemotherapy: relevance of breast carlcer subtype [J]. J Clin Oncol,2011,29(6) :660-666.
9Jensen L R,Garzon B, Heldahl M G,et al. Diffusion-weighted and dynamic contrast-enhanced MRI in evaluation of early treatment effects during neoadjuvant chemotherapy in breast cancer patients [J]. J Magn Reson Imaging, 2011,34 ( 5 ) : 1099-1109.
10Richard R, Thomassin I, Chapellier M, et al. Diffusion-weigh- ted MRI in pretreatment prediction of response to neoadju- vant chemotherapy in patients with breast cancer[J]. Eur Ra- dioi,2013,23(9) :2420-2431.
